Erythroid differentiation of myeloblast induced by gilteritinib in relapsed FLT3-ITD-positive acute myeloid leukemia.
作者信息
Yun Hyun Don, Nathan Sunita, Larson Melissa, Hussain Mohammad J, Katz Deborah A, Varma Ankur, Miller Ira, Ustun Celalettin
机构信息
Division of Hematology, Oncology and Cell Therapy, Department of Medicine, and.
Section of Hematopathology, Department of Pathology, Rush University, Chicago, IL.
出版信息
Blood Adv. 2019 Nov 26;3(22):3709-3712. doi: 10.1182/bloodadvances.2019000775.
Abstract
摘要
相似文献
1
Erythroid differentiation of myeloblast induced by gilteritinib in relapsed FLT3-ITD-positive acute myeloid leukemia.吉瑞替尼诱导复发的FLT3-ITD阳性急性髓系白血病中髓母细胞的红系分化
Blood Adv. 2019 Nov 26;3(22):3709-3712. doi: 10.1182/bloodadvances.2019000775.
2
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.吉瑞替尼对复发或难治性急性髓系白血病中FLT3的选择性抑制作用：一项多中心、首例人体、开放标签的1-2期研究。
Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20.
3
[Gilteritinib for pediatric FLT3 internal tandem duplication-positive recurrent acute myeloid leukemia].吉列替尼用于治疗儿科FLT3内部串联重复阳性复发性急性髓系白血病
Rinsho Ketsueki. 2020;61(4):322-326. doi: 10.11406/rinketsu.61.322.
4
Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.在 FLT3 突变的急性髓系白血病的临床前模型中，Bcl-2 的抑制作用与米哚妥林和吉特替尼协同增强抗白血病活性。
Clin Cancer Res. 2019 Nov 15;25(22):6815-6826. doi: 10.1158/1078-0432.CCR-19-0832. Epub 2019 Jul 18.
5
Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor.同种异体二次移植后接受吉特替尼治疗后，FLT3-ITD AML 移植后复发患者获得持久缓解。
Int J Hematol. 2020 Aug;112(2):249-253. doi: 10.1007/s12185-020-02858-1. Epub 2020 Mar 17.
6
Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation.异基因造血干细胞移植后伴 FLT3-ITD 突变的急性髓系白血病髓外孤立复发采用吉特替尼治疗获得成功。
Int J Hematol. 2020 Aug;112(2):243-248. doi: 10.1007/s12185-020-02855-4. Epub 2020 Mar 13.
7
Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia.吉特替尼治疗复发和/或难治性 FLT3 突变型急性髓系白血病。
Expert Rev Clin Pharmacol. 2019 Sep;12(9):841-849. doi: 10.1080/17512433.2019.1657009. Epub 2019 Aug 27.
8
[Pharmacological and clinical profile of gilteritinib (Xospata tablets 40 mg), a therapeutic agent for relapsed or refractory FLT3-mutated acute myeloid leukemia].吉瑞替尼（Xospata片剂，40毫克）的药理及临床概况，一种用于复发或难治性FLT3突变急性髓系白血病的治疗药物
Nihon Yakurigaku Zasshi. 2021;156(1):37-46. doi: 10.1254/fpj.20050.
9
Gilteritinib induces differentiation in relapsed and refractory -mutated acute myeloid leukemia.吉特替尼诱导复发/难治性突变型急性髓系白血病的分化。
Blood Adv. 2019 May 28;3(10):1581-1585. doi: 10.1182/bloodadvances.2018029496.
10
Gilteritinib: First Global Approval.吉特替尼：全球首次批准。
Drugs. 2019 Feb;79(3):331-339. doi: 10.1007/s40265-019-1062-3.
引用本文的文献
1
Monocytic Differentiation in Acute Myeloid Leukemia Cells: Diagnostic Criteria, Biological Heterogeneity, Mitochondrial Metabolism, Resistance to and Induction by Targeted Therapies.急性髓系白血病细胞中的单核细胞分化：诊断标准、生物学异质性、线粒体代谢、对靶向治疗的耐药性和诱导作用。
Int J Mol Sci. 2024 Jun 8;25(12):6356. doi: 10.3390/ijms25126356.
2
Evaluation of hypereosinophilia in a case of -mutant acute myeloid leukemia treated with gilteritinib.吉瑞替尼治疗 - 突变型急性髓系白血病致嗜酸性粒细胞增多症的评估。
Cold Spring Harb Mol Case Stud. 2023 Jul 11;9(3). doi: 10.1101/mcs.a006279. Print 2023 Jun.
3
Fms-like tyrosine kinase 3 is a regulator of the cardiac side population in mice.Fms 样酪氨酸激酶 3 是小鼠心脏侧群的调节因子。
Life Sci Alliance. 2021 Dec 13;5(3). doi: 10.26508/lsa.202101112. Print 2022 Mar.
4
A new FLT3 inhibitor with two cases: the gilteritinib experience.一种新型FLT3抑制剂及两例病例：吉瑞替尼的经验
Am J Blood Res. 2021 Jun 15;11(3):271-278. eCollection 2021.
5
Joint profiling of DNA and proteins in single cells to dissect genotype-phenotype associations in leukemia.单细胞中 DNA 和蛋白质的联合分析，解析白血病中基因型-表型相关性。
Nat Commun. 2021 Mar 11;12(1):1583. doi: 10.1038/s41467-021-21810-3.
6
Megakaryocytic Expansion in Gilteritinib-Treated Acute Myeloid Leukemia Patients Is Associated With AXL Inhibition.吉列替尼治疗的急性髓系白血病患者中的巨核细胞扩增与AXL抑制有关。
Front Oncol. 2020 Dec 9;10:585151. doi: 10.3389/fonc.2020.585151. eCollection 2020.
7
MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system.MERTK 在癌症治疗中的作用：靶向肿瘤细胞和免疫系统中的受体酪氨酸激酶。
Pharmacol Ther. 2020 Sep;213:107577. doi: 10.1016/j.pharmthera.2020.107577. Epub 2020 May 14.
本文引用的文献
1
Gilteritinib induces differentiation in relapsed and refractory -mutated acute myeloid leukemia.吉特替尼诱导复发/难治性突变型急性髓系白血病的分化。
Blood Adv. 2019 May 28;3(10):1581-1585. doi: 10.1182/bloodadvances.2018029496.
2
Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.与依尼西单抗相关的分化综合征，一种选择性突变型异柠檬酸脱氢酶 2 抑制剂：一项 1/2 期研究的分析。
JAMA Oncol. 2018 Aug 1;4(8):1106-1110. doi: 10.1001/jamaoncol.2017.4695.
3
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.米哚妥林联合化疗治疗伴有FLT3突变的急性髓系白血病
N Engl J Med. 2017 Aug 3;377(5):454-464. doi: 10.1056/NEJMoa1614359. Epub 2017 Jun 23.
4
Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.使用靶向突变型异柠檬酸脱氢酶1（IDH1）抑制剂AG-120治疗的急性髓系白血病伴IDH1突变患者的临床分化及分化综合征证据
Clin Lymphoma Myeloma Leuk. 2016 Aug;16(8):460-5. doi: 10.1016/j.clml.2016.04.006. Epub 2016 May 5.
5
Fms-like tyrosine kinase 3 (Flt3) ligand depletes erythroid island macrophages and blocks medullar erythropoiesis in the mouse.Fms样酪氨酸激酶3（Flt3）配体可消耗小鼠红系岛巨噬细胞并阻断其骨髓红细胞生成。
Exp Hematol. 2016 Mar;44(3):207-12.e4. doi: 10.1016/j.exphem.2015.11.004. Epub 2015 Dec 1.
6
Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect.索拉非尼在FLT3/ITD阳性急性髓性白血病移植后复发中的应用：成熟诱导和细胞毒性作用。
Haematologica. 2014 Nov;99(11):e222-4. doi: 10.3324/haematol.2014.109975. Epub 2014 Jul 11.
7
In vivo evidence for an instructive role of fms-like tyrosine kinase-3 (FLT3) ligand in hematopoietic development.体内证据表明fms样酪氨酸激酶-3（FLT3）配体在造血发育中具有指导作用。
Haematologica. 2014 Apr;99(4):638-46. doi: 10.3324/haematol.2013.089482. Epub 2014 Jan 24.
8
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.靶向抑制白血病细胞中的突变 IDH2 诱导细胞分化。
Science. 2013 May 3;340(6132):622-6. doi: 10.1126/science.1234769. Epub 2013 Apr 4.
9
Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.伴有低等位基因负担 FLT3-ITD 突变和同时性 NPM1 突变的急性髓系白血病患者的有利结局：与缓解后治疗相关。
Blood. 2013 Apr 4;121(14):2734-8. doi: 10.1182/blood-2012-06-431122. Epub 2013 Feb 1.
10
Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.FLT3/ITD AML 中 FLT3 抑制诱导体内末端髓系分化。
Blood. 2012 Nov 15;120(20):4205-14. doi: 10.1182/blood-2012-01-402545. Epub 2012 Sep 25.
Zotero 插件